Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

4.15
+2.94242.98%
Pre-market: 3.60-0.5500-13.25%09:27 EDT
Volume:129.87M
Turnover:341.28M
Market Cap:13.14M
PE:-0.58
High:4.40
Open:1.30
Low:1.30
Close:1.21
Loading ...

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.d.

THOMSON REUTERS
·
01 Apr

Press Release: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Dow Jones
·
01 Apr

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
28 Mar

BRIEF-Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas

Reuters
·
26 Mar

Sonnet Biotherapeutics Successfully Completes First Safety Review of Son-1010 in Combination With Trabectedin in Certain Sarcomas

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics Holdings : Safety Review Committee Found No Unexpected Toxicities in Early Dosing of Son-1010 in First 7 Patients at Mtd

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics : Annual Review Showed Extended Safety of Son-1010 Monotherapy at Mtd With Clinical Benefit in 83% of Patients at That Dose

THOMSON REUTERS
·
26 Mar

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

GlobeNewswire
·
26 Mar

Sonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18

TIPRANKS
·
19 Mar

Sonnet Biotherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein

THOMSON REUTERS
·
19 Mar

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

GlobeNewswire
·
19 Mar

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire
·
11 Mar

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswire
·
26 Feb

BRIEF-Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships

Reuters
·
19 Feb

Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

THOMSON REUTERS
·
19 Feb

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

GlobeNewswire
·
19 Feb

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

GlobeNewswire
·
18 Feb

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Sonnet BioTherapeutics appoints McAndrew as Chief Business Officer

TIPRANKS
·
13 Feb

BRIEF-Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer

Reuters
·
13 Feb